JP Morgan Comments on Trial Completion of Baxter's Alzheimer's Drug

“We confirmed on Wednesday that the first of Baxter's (NYSE: BAX) two phase III IVIG for Alzheimer's trials has now completed enrollment,” JP Morgan wrote in a report this morning.

“An additional 30 patients were enrolled in the trial versus plan bringing total enrollment to 390 patients randomized to either (a) 400mg of IVIG/kg of bodyweight every 2 weeks; (b) 200mg of IVIG/kg; or (c) a placebo solution. Patients will be dosed and followed for 18 months with the last patient now expected to reach follow-up in January 2013. Given time for data gathering and analysis, we should see headline data by mid-2013.”

Baxter closed Wednesday at $60.58.